Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- Memorial Sloan Kettering Basking Ridge (consent and Follow-Up Only)
Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (consent and Follow Up Only)
Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (consent and Follow Up Only)
Montvale, New Jersey, United States
- Memorial Sloan Kettering Commack (consent and Follow-Up Only)
Commack, New York, United States
- Memorial Sloan Kettering Westchester
Harrison, New York, United States
- Northwell Health (data Collection Only)
Manhasset, New York, United States
- Columbia University
New York, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- University of Rochester Medical Center
Rochester, New York, United States
- Memorial Sloan Kettering Nassau (consent and Follow Up Only)
Uniondale, New York, United States
- Tennessee Oncology
Nashville, Tennessee, United States
- Texas Transplant Institute
San Antonio, Texas, United States
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2015
- Primary completion
- 31 Oct 2026
- Completion
- 31 Oct 2026
- Last update posted
- 26 Nov 2025
- Registered enrollment
- 59
- Registry id
- NCT02570542
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.